Joshua Kazam - Allogene Therapeutics Co-Founder, Director
| ALLO Stock | USD 1.87 0.03 1.63% |
Director
Mr. Joshua A. Kazam is CoFounder, Director of the Company. Mr. Kazam is one of our cofounders and served as our President from November 2017 until June 2018. He was a founder of Kite and served as a member of Kites board of directors from Kites inception in June 2009 until October 2017. Mr. Kazam also served as Kites President until September 2010. In June 2009, Mr. Kazam cofounded Two River Consulting, LLC, a lifescience consulting and investment firm. Since October 2005, he has also served as an officer and director and is the coowner of Riverbank Capital Securities, Inc., a FINRA member broker dealer. From 2002 to 2004, Mr. Kazam served as the Director of Investment Management for the Orion Biomedical Fund, a private equity fund focused on biotechnology investments. Mr. Kazam has served on the board of directors of Capricor Therapeutics, Inc., a publicly reporting biotechnology company, since May 2005, and Vision Path, Inc. since May 2016, Kronos Bio, Inc. since June 2017 and Platinum Eagle Acquisition Corporationration, a blank check company formed for the purpose of effecting a business combination with one or more businesses, since January 2018. Mr. Kazam served on the board of directors of Velcera, Inc. from 2003 until it was acquired by Perrigo Company plc in 2013. He is also the cofounder and has served on the board of directors of Veterinary Prime, Inc. since its inception in February 2015 and has served as the President of Desert Flower Foundation since June 2016 since 2018.
| Age | 47 |
| Tenure | 6 years |
| Address | 210 East Grand Avenue, South San Francisco, CA, United States, 94080 |
| Phone | 650 457 2700 |
| Web | https://www.allogene.com |
Joshua Kazam Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joshua Kazam against Allogene Therapeutics stock is an integral part of due diligence when investing in Allogene Therapeutics. Joshua Kazam insider activity provides valuable insight into whether Allogene Therapeutics is net buyers or sellers over its current business cycle. Note, Allogene Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allogene Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joshua Kazam over six months ago Acquisition by Joshua Kazam of 116120 shares of Allogene Therapeutics at 5.7 subject to Rule 16b-3 |
Allogene Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2582) % which means that it has lost $0.2582 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5415) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics' management efficiency ratios could be used to measure how well Allogene Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of December 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.57. At this time, Allogene Therapeutics' Total Assets are very stable compared to the past year. As of the 22nd of December 2024, Non Current Assets Total is likely to grow to about 245.6 M, while Net Tangible Assets are likely to drop about 732.1 M.Similar Executives
| Found 9 records | DIRECTOR Age | ||
| Yasunori Kaneko | Arcus Biosciences | 66 | |
| Jeff Cohn | Heron Therapeuti | N/A | |
| Andrew Perlman | Arcus Biosciences | 72 | |
| David Lacey | Arcus Biosciences | 67 | |
| Patrick Machado | Arcus Biosciences | 55 | |
| John Poyhonen | Heron Therapeuti | 64 | |
| Kathryn Falberg | Arcus Biosciences | 60 | |
| Kimberly Manhard | Heron Therapeuti | 64 | |
| Antoni Ribas | Arcus Biosciences | 53 | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 |
Allogene Therapeutics Leadership Team
Elected by the shareholders, the Allogene Therapeutics' board of directors comprises two types of representatives: Allogene Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allogene. The board's role is to monitor Allogene Therapeutics' management team and ensure that shareholders' interests are well served. Allogene Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allogene Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Moore, Executive Officer | ||
| Rafael MD, Ex RD | ||
| Joshua Kazam, Co-Founder, Director | ||
| Geoffrey Parker, Executive CFO | ||
| FACS FACS, CoFounder Chairman | ||
| Susan Lundeen, Chief Officer | ||
| Veer Bhavnagri, G Officer | ||
| Earl Esq, General Officer | ||
| Christine Cassiano, Chief Officer | ||
| Annie Yoshiyama, Corporate VP | ||
| Yinlin Chen, Senior Finance | ||
| MD FACS, CoFounder Chairman | ||
| Alison Moore, Chief Technical Officer | ||
| David JD, Secretary | ||
| Eric Schmidt, Chief Officer | ||
| Stephen Cheng, Chief Officer | ||
| Barbra Sasu, Chief Scientific Officer |
Allogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allogene Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 185.66 M | ||||
| Shares Outstanding | 209.67 M | ||||
| Shares Owned By Insiders | 17.42 % | ||||
| Shares Owned By Institutions | 80.00 % | ||||
| Number Of Shares Shorted | 31.17 M | ||||
| Price To Earning | (3.30) X | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 9,118 X |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.69 | DRTS | Alpha Tau Medical | PairCorr |
| 0.64 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.61 | VCYT | Veracyte | PairCorr |
| 0.6 | VCEL | Vericel Corp Ord | PairCorr |
| 0.58 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.